Totally fair observation, and I don’t think it’s cynical at all. If a company like GSK or Roche had submitted the exact same data package, it likely wouldn’t be caught in the same drag. That’s just how the system works when a small, underfunded biotech with no political leverage is trying to rewrite the rulebook.
But here’s the flip side.
The fact that DCVax got this far without big pharma backing, institutional protection, or political cover actually says more about the product than most people realize.
GSK could’ve bought Cognate. Pfizer could’ve funded the Phase III. AstraZeneca is 7 miles down the road from Advent and could’ve taken it over at any point. But they didn’t, and NWBO still built the process, validated the product, and helped MHRA create SI 87 around it.
And not to mention, if this had been handed over to a major player early on, retail investors would’ve never had a shot at participating in the upside. The only reason there’s even a window for generational wealth here is because it wasn’t absorbed by big pharma from day one.
Now the irony is this: those same companies that passed early will likely have to license, partner, or build around it, because they can’t afford to acquire it outright anymore. Too much IP is locked up. Too much infrastructure is already in place. And too much of the global regulatory groundwork has already been laid.
And when Linda Powers used the word “franchise,” that wasn’t casual, it was declarative.
You don’t call it a franchise unless you know the model can scale. That it’s repeatable. Tissue-in, immune-out. Not just for glioblastoma. For dozens of solid tumors. Across regulatory pathways. Across markets.
That word signaled something most missed:
This isn’t about getting approval. This is about building the platform others will have to rent.
So yes, the delays are frustrating. But this platform didn’t just survive politics.
It outmaneuvered them.
And now the same groups that once passed will either partner, or get boxed out.
Bullish
AI
Market Data 
Markets 
